AI assistant
Oxurion NV — Major Shareholding Notification 2023
Dec 1, 2023
3987_mrq_2023-12-01_f793636b-a958-4190-b238-b1fa93748c64.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
December 1, 2023
Regulated Information
Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1.
Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtue of the acquisition and sale of voting securities. See Annex 2.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
| Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 [email protected] |
US Conway Communications Mary T. Conway [email protected] |
|---|---|
| Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 [email protected] |
- Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.
ANNEX 1
________
| FSMA | FINANCIAL SERVICES AND MARKETS AUTHORITY |
Transparency notification Form TR-1 BE PARTI |
|
|---|---|---|---|
| 1) Status of the notification | |||
| Final | |||
| 2) Issuer | |||
| Identification number | Name OXURION 0881-620-924 |
||
| 3) Reason for the notification | |||
| Acquisition or disposal of voting securities or voting rights | |||
| Downward crossing of the lowest threshold | |||
| 4) Notification by | |||
| A person that notifies alone | ÷. | ||
| 5) Persons subject to the notification requirement | |||
| Name | Address (for legal entities) | ||
| Atlas Special Opportunities LLC | 2500 Westchester Avenue, Suite 401, Purchase, NY 10577 | ||
| 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies) | |||
| Name | Address (for legal entities) | ||
| Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6 |
Part II | ||
| 7) Date on which the threshold is crossed | |||
| 13/11/2023 (DD/MM/YYYY) | |||
| 8) Threshold that is crossed (in %) | |||
| u | If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10 |
10) Notified details
| A) Voting rights | Previous notification | After the transaction | |||
|---|---|---|---|---|---|
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities |
Linked to securities | Not linked to the securities |
|
| Atlas Special Opportunities LLC | 232.919.254 | $\circ$ | 0.00% | ||
| TOTAL | ٥ | 0.00% | 0.00% |
$0.00\%$ $\mathbf 0$ $0.00\%$
$\pm$
TOTAL D 0 0 0.00%
Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".
The totals, subtotals and % will be updated once you have clicked on .
Sign Envelope ID: F1BD79BA-C3D9-4995-8CCF-60F38B4394FF
| B) Equivalent financial instruments | After the transaction | ||||||
|---|---|---|---|---|---|---|---|
| Holders of equivalent financial instruments |
Type of financial instrument | Expiration date | Exercise period or date |
# of voting rights that may be acquired if the Instrument is exercised |
% of voting rights | Settlement | |
| TOTAL | $\bullet$ | 0.00% |
The totals will be updated once you have clicked on
| TOTAL (A & B) | # of voting rights % of voting rights | |
|---|---|---|
| CALCULATE | 0.00% |
11) Full chain of controlled undertakings through which the holding is effectively held, if applicable
| Atlas Special Opportunities LLC is not a controlled entity. | ||
|---|---|---|
12) In case of proxy voting for only one GM
| JAN 1965 | |||
|---|---|---|---|
| Holder | Il cease to hold / W. will hold again |
$-90$ жÆ voting big |
13) Additional information
| On 9 November 2023, Atlas Special Opportunities LLC held 157,227,832 shares in Oxurion NV (= 5.05%, with denominator = 3,112,043,514). On 10 November 2023, Atlas Special Opportunities LLC sold 65,678,385 shares in Oxurion NV, as a result of which its shareholding decreased to 91,549,447 shares (= 2.94%, with denominator = 3,112,043,514). On 13 November 2023, Atlas Special Opportunities LLC sold |
|---|
| 91,549,447 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, with denominator = 3,112,043,514). |
| Done at New York | ||
|---|---|---|
| On | 17/11/2023 (DD/MM/YYYY) | |
| Name & capacity Patrick Vance, proxyholder | DocuSigned by: Patrick Vance Signature 55348237829544C |
ANNEX 2
| FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY |
Transparency notification Form TR-1 BE PARTI |
|
|---|---|---|
| 1) Status of the notification | ||
| Final | ||
| 2) Issuer | ||
| Name OXURION Identification number 0881-620-924 |
||
| 3) Reason for the notification | ||
| Acquisition or disposal of voting securities or voting rights | ||
| 4) Notification by | ||
| A person that notifies alone | ÷. | |
| 5) Persons subject to the notification requirement | ||
| Name | Address (for legal entities) | |
| 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies) | ||
| Name | Address (for legal entities) | |
| Atlas Special Opportunities LLC | 2500 Westchester Avenue, Suite 401, Purchase, NY 10577 | |
| persons referred to in Sections 5 and 6 | Please continue entering the information in part II concerning the Part II |
|
| 7) Date on which the threshold is crossed | ||
| 17/11/2023 (DD/MM/YYYY) | ||
| 8) Threshold that is crossed (in %) | ||
| If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10 |
9) Denominator
3,489,458,972 Please enter the denominator before filling in the data
10) Notified details
| A) Voting rights | Previous notification | After the transaction | |||
|---|---|---|---|---|---|
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities |
Linked to securities | Not linked to the securities |
|
| Atlas Special Opportunities LLC | 241,545,893 | 6.92% | |||
| TOTAL | 241,545,893 | 6.92% | 0.00% |
$\pm$
Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will b
gn Envelope ID: 7F03E731-92D9-4BC6-8FCE-52174CF89325
| B) Equivalent financial instruments | After the transaction | ||||||
|---|---|---|---|---|---|---|---|
| Holders of equivalent financial instruments |
Type of financial instrument | Expiration date | Exercise period or date |
# of voting rights that may be acquired if the instrument is exercised |
% of voting rights | Settlement | |
| $+1$ | |||||||
| TOTAL | $\bf{0}$ | 0.00% |
The totals will be updated once you have clicked on
| TOTAL (A & B) | # of voting rights % of voting rights | ||
|---|---|---|---|
| CALCULATE | 241,545,893 | 6.92% |
12) In case of proxy voting for only one GM
| ,,,,,,, | |||
|---|---|---|---|
| Holder | will cease to hold / will hold again |
voting rights as of |
13) Additional information
| On 15 November 2023, Atlas Special Opportunities LLC purchased 135,869,565 shares in Oxurion NV, as a result of which its shareholding increased to 135,869,565 shares (= 4,18%, with denominator = |
|---|
| 3,247,913,079). On 17 November 2023, Atlas Special Opportunities LLC purchased 241,545,893 shares in Oxurion NV, as a result of which its shareholding increased to 377,415,458 shares (= 10.82%, with |
| denominator = 3,489,458,972). On the same day, Atlas Special Opportunities LLC sold 135,869,565 shares in Oxurion NV, as a result of which its shareholding decreased to 241,545,893 shares (= 6.92%, with |
| denominator = 3.489.458.972). |
| Done at New York | ||
|---|---|---|
| On | 24/11/2023 (DD/MM/YYYY) | |
| Name & capacity Patrick Vance, proxyholder |
Attachments
- $\frac{\epsilon}{N}$